AtaiBeckley Inc. (ATAI)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $7.35
- As of
Kresmion compiles this page from ATAI's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AtaiBeckley Inc. (ATAI): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-11.
See the full ATAI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ATAI on one page. Preview it with sample data, then open it live with a free account.
Preview the ATAI dossierActive signals for ATAI
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 11.8%, EPS $-0.09 vs $-0.102 estimate
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in ATAI
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 59% of ATAI (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 58% of ATAI (2026Q2)
- highCONSENSUS_BUY
4 tracked funds increased ATAI this 2026Q1 - institutional consensus
FREE, NO ACCOUNT
Every signal on ATAI, as it fires
You are seeing 5 of 15 signals recorded on ATAI since 2026-05-30.
The five above landed across 3 days. The other 10 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ATAI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 04650F101 · 2026Q2 | $11.1M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 04650F101 · 2026Q2 | $9.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 04650F101 · 2026Q2 | $4.3M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 04650F101 · 2026Q2 | $77K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ATAI
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ATAI against its peers
ATAI's operating margin of -15751.1% ranks in the 10th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | ATAI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4.1M USD | 84.0M USD | 16 | 15 |
| Operating margin | -15751.1% | -307.4% | 10 | 14 |
| Net margin | -16142.0% | -186.1% | 10 | 14 |
| Return on equity | -297.5% | -31.7% | 7 | 22 |
| 1 year | n/a | 23.4% | n/a | 21 |
Peers (23): PGEN, BEAM, ZLAB, MBX, NAMS, ELVN, RCUS, DYN, DNLI, IRON, SLS, RXRX, CLDX, ADMA, NRIX, IMNM, CELC, AUPH, ARQT, GRTX, PHVS, ACAD, BCRX. Left out: ZLDPF (no annual filing), PBLS (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ATAI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ATAI on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ATAI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.